If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Sales and Marketing » Marketing Management » Designing Marketing Strategies » Product Positioning and Differentiation
Download FREE Excerpt
22 Info Graphics
4 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
Effexor was the first approved dual method of action Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) depression treatment. When it hit the market in 1994, Effexor faced two established classes of antidepressants with Prozac, a Selective Serotonin Reuptake Inhibitor (SSRI), dominating the market. Three years after launch, Effexor sales were stalled at $230 million a year. Over the next decade, Wyeth executed a series strategies - with Effexor's superior efficacy as the centerpiece - that took the therapy to $4 billion in annual sales by 2007.
This case study reviews the multiple strategies - from a new formulation and additional indications to expanded sales force and scientific publications - Wyeth used to patiently build Effexor into a blockbuster brand. Through a series of well-integrated clinical and commercial activities, the company established and promoted the brand's superior efficacy.
Using secondary research, Best Practices, LLC created this case study to assess and highlight the winning strategies that led to Effexor becoming a market leader. Executives can use this study to understand Wyeth's approach to using superior efficacy to help a product that's entering a crowded market.
Insights were drawn from extensive secondary research.